PFE
Pfizer Inc.
Price History
Why Is PFE ▼ Down Today?
-0.36%
Pfizer dips slightly, underperforming sector amidst vaccine mandate news
Pfizer (PFE) experienced a modest decline of 0.358% today, closing at $25.05, underperforming its sector which saw an average gain of 0.48%. This slight downward movement occurred amidst news regarding a vaccine mandate case and an article raising questions about the company's high-yielding dividend.
Key Drivers
Generated by Highly Regarded's proprietary market analysis engine. Not financial advice.
Financial Highlights
Income Statement
Balance Sheet
Cash Flow
Highly Regarded Analysis
Executive Summary
Pfizer Inc. is a leading global biopharmaceutical company navigating a transition period following the peak of its COVID-19 product revenues. The company reported better-than-expected Q1 2026 earnings, with an adjusted EPS of $0.75 and revenues of $14.5 billion, exceeding analyst estimates. This performance was driven by a 7% operational growth in non-COVID products and a 22% increase from recently launched and acquired products. Pfizer is strategically repositioning itself in high-growth therapeutic areas, particularly oncology through the Seagen acquisition, and entering the obesity market via the Metsera deal. Despite reaffirming its full-year 2026 financial guidance, the company faces a significant patent cliff between 2026 and 2028, potentially impacting annual revenues by $17-18 billion. Pfizer maintains a robust R&D pipeline with 102 programs in development and 96 active Phase 3 trials, aimed at offsetting these upcoming losses.
Bull Case
Pfizer successfully navigates the patent cliff by effectively leveraging its robust and diversified pipeline, particularly new assets in oncology (post-Seagen acquisition) and obesity (Metsera acquisition). Strong clinical trial readouts and swift regulatory approvals for key pipeline drugs, such as Vepdegestrant and Berobenatide, drive significant new revenue streams that more than offset losses from expiring patents. Enhanced operational efficiencies and strategic investments in AI/digital capabilities lead to improved profit margins and accelerated R&D timelines. Consistent strong performance from recently launched and acquired products, coupled with successful new product launches, results in sustained revenue and EPS growth, leading to capital appreciation alongside its attractive dividend.
Bear Case
The impact of the patent cliff, estimated to be between $17-18 billion in annual revenue erosion, proves more severe than anticipated, and Pfizer's new pipeline products fail to generate sufficient sales to compensate. Intense competition in the oncology and obesity markets significantly limits market penetration and profitability of new drugs. Integration costs and asset impairments from the Seagen and Metsera acquisitions weigh heavily on financial results, and R&D investments do not yield expected returns. Persistent bearish technical signals lead to further stock price declines, and any unforeseen legal or regulatory setbacks for key pipeline assets exacerbate financial challenges.
Technical Outlook
Recent technical analysis indicates a bearish sentiment for PFE, with the stock price trading below the 21-, 50-, and 100-day Simple Moving Averages (SMAs). The MACD (Moving Average Convergence Divergence) also confirms ongoing selling pressure. Key support levels are identified between $23.00 and $23.62. A break below these levels could lead to further declines towards $22.00 or potentially $20.00. Over the past year, the stock has shown a modest 2.9% increase, underperforming the broader industry's 17.2% gain.
Fundamental Health
Pfizer's fundamental health shows a mix of strengths and challenges. Full-year 2025 revenues were $62.6 billion, a 2% operational decline year-over-year, primarily due to decreased COVID-19 product sales; however, excluding COVID products, revenues grew 6% operationally. Q1 2026 revenue increased 5% year-over-year to $14.5 billion, with non-COVID revenue growing 7% operationally. The company's Q1 2026 adjusted diluted EPS of $0.75 beat estimates, and it reaffirmed full-year 2026 adjusted diluted EPS guidance of $2.80 to $3.00. Pfizer boasts a Q1 2026 net margin of 18.66%, outperforming many competitors. Despite a 9.32% year-on-year drop in Q1 2026 net income, this was less severe than the broader industry contraction. The company invested $10.4 billion in R&D and $8.8 billion in business development in 2025, while also returning $9.8 billion to shareholders through dividends.
Key Catalysts
- Positive Phase 3 data readouts and regulatory approvals for key pipeline assets in oncology (e.g., PADCEV, ELREXFIO) and obesity (Berobenatide program), as well as the Lyme Disease Vaccine Candidate.
- Successful integration of and strong performance from assets acquired through the Seagen and Metsera deals.
- Effective management and mitigation of revenue losses due to patent expirations for key drugs like Eliquis, Prevnar 13, and Xtandi (2026-2027).
- Realization of anticipated cost savings and operational efficiencies from ongoing productivity initiatives, targeting $7.2 billion in net cost savings by the end of 2026.
This analysis was conducted by Highly Regarded's proprietary market analysis engine. It is not financial advice. Always do your own research and consult a financial advisor before making investment decisions.
Go Deeper on PFE
Key Stats
Next Earnings
PFE News
No recent news for PFE.
